Pharmaceutical

Argenica Therapeutics Limited

Preclinical Data Shows ARG-007 Inhibits One Of The Main Causes Of Alzheimer’s Disease

Argenica Therapeutics Limited (ASX: AGN) (“Argenica” or the “Company”), a biotechnology company developing novel therapeutics to reduce brain tissue death after brain injury, is pleased to announce positive initial preclinical data on ARG- 007’s ability to inhibit human recombinant Amyloid-Beta (Abeta) aggregation in a preclinical (in vitro) model of Alzheimer’s Disease. Abeta aggregation is thought to be one of the main causes of Alzheimer’s Disease, with the Abeta accumulation in senile plaques causing memory loss and confusion.1


Highlights:

  • Preclinical data has shown ARG-007 significantly inhibited the aggregation of human recombinant Amyloid-Beta (Abeta) in a cell-free Abeta aggregation assay model.
  • Abeta aggregation is thought to be one of the main causes of Alzheimer’s Disease, with the Abeta accumulation in senile plaques causing memory loss and confusion.
  • At 16 hours following ARG-007 administration, a 25 µM dose of ARG-007 reduced Abeta aggregation by more than 50% compared to vehicle controls.
  • Argenica will now progress to animal studies to further confirm the efficacy of ARG-007 in Alzheimer’s Disease and will update the market as milestones are meet.
  • The global Alzheimer's therapeutics market size was valued at USD4.04 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 16.2% from 2022 to 2030.

Argenica engaged leading preclinical Contract Research Organisation QPS, based in Austria, to undertake the study. The aim of the study was to determine the effects of ARG-007 in comparison to controls in inhibiting human recombinant Abeta aggregation using the cell- free Abeta aggregation assay.

In this study, three concentrations of ARG-007 were used to determine the drug’s efficacy in inhibiting human recombinant Abeta aggregation – 2.5 µM, 7.5 µM and 25 µM. Abeta aggregation was assessed at 4 hours, 10 hours and 16 hours post administration of ARG-007. The results of this study show ARG-007 has a positive effect in inhibiting Abeta aggregation at the 10 hour and 16 hour post administration time points, compared to the vehicle controls. At the 16-hour time point, when Abeta had reached maximum aggregation, all three concentrations of ARG-007 showed a large significant reduction in Abeta aggregation compared to the control, with the 25 µM showing a greater than 50% reduction in Abeta aggregation, as shown in the graph below:

Concentration of ARG-007

Figure 1. An assessment of the extent of Abeta aggregation inhibition at Abeta plateau, 16 hours after the administration of ARG-007, at three different concentrations of the drug, 2.5 µM, 7.5 µM and 25 µM. Data are shown as % of vehicle control (VC) and displayed as bar graphs with group means +SEM (n=4 per group). Statistical analysis involved a two-tailed ANOVA followed by Bonferroni’s Multiple comparison Test (post hoc test) compared to VC *p<0.05; **p<0.01; ***p<0.001.

This in vitro (in petri dish) cell-free Abeta aggregation assay model provides important insights into the pathogenesis of Alzheimer’s Disease by simulating the disease in a less complex environment compared to in vivo (in living organism) systems. It provides preliminary information on mechanisms and possible protective roles of ARG-007 in Alzheimer’s Disease.

Dr Liz Dallimore, Argenica’s Managing Director, said“This is extremely encouraging data showing a potential new indication for ARG-007. It is well recognised that Abeta aggregation in the brain plays a key role in initiating Alzheimer’s Disease, and therefore a safe therapeutic drug that can reduce Abeta aggregation is a huge opportunity. We look forward to continuing to progress this exciting opportunity into further animal studies.”


Click here for the full ASX Release

This article includes content from Argenica Therapeutics Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

The Conversation (0)

Jamieson Wellness Inc. Announces Filing of Management Information Circular for Annual and Special Meeting of Shareholders

Jamieson Wellness Inc. (" Jamieson Wellness " or the " Company ") (TSX: JWEL) announced today that the Company has filed its management information circular (" Circular ") and related materials (together with the Circular, the " Meeting Materials ") for the annual and special meeting of shareholders (the " Shareholders ") of Jamieson Wellness to be held on May 18, 2023 at 2:00 p.m. (Eastern Daylight Time) at the offices of McCarthy Tetrault LLP, 66 Wellington Street West, Toronto, Ontario, Suite 5300, and online via live audio webcast at https:meetnow.globalMMUNSXJ (the " Meeting ").

The Company is pleased to be offering Shareholders the option to participate in-person at this year's Meeting, while continuing to offer Shareholders the option to participate online via live audio webcast.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its first-quarter 2023 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, April 27. During the call, company executives will provide an overview of Merck's performance for the quarter.

Investors, journalists and the general public may access a live audio webcast of the call via this weblink . A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures, and slides highlighting the results, will be available at www.merck.com .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

FDA Converts to Full Approval Indication for KEYTRUDA® for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High or Mismatch Repair Deficient Solid Tumors

KEYTRUDA is approved for the treatment of adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to KEYTRUDA, Merck's anti-PD-1 therapy, for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. The conversion from an accelerated to a full (regular) approval is based on results from the Phase 2 KEYNOTE-158, KEYNOTE-164 and KEYNOTE-051 trials and includes data in 504 adult and pediatric patients across more than 30 types of cancer. This marks the first full approval for an immunotherapy based on a predictive biomarker, regardless of solid tumor type.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

BetterLife's Non-hallucinogenic LSD For Treating Mood Disorders Highlighted in Drug Discovery & Development Article

BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR  OTCQB: BETRF FRA: NPAU ), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that, an article titled "Non-hallucinogenic LSD derivative reduces depression symptoms in preclinical studies," based on BetterLife's lead candidate BETR-001 (2-bromo-LSD) was published by Drug Discovery & Development on March 22, 2023.

The Drug Discovery & Development article describes and adds further comments to the positive data and extensive pharmacological characterization of BETR-001 which were published recently in the peer-reviewed journal Cell Report s. These studies were performed by BetterLife in collaboration with several leading scientists in this field: Dr. Adam L. Halberstadt (University of California San Diego, USA), Dr. Argel Aguilar-Valles (Carleton University, Canada), and Dr. John D. McCorvy (Medical College of Wisconsin, USA).

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

KEYTRUDA® Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status

KEYTRUDA plus chemotherapy reduced risk of disease progression or death by 46% in patients whose cancer was mismatch repair proficient (pMMR) and by 70% in patients whose cancer was mismatch repair deficient (dMMR), compared to chemotherapy alone

Results from Phase 3 NRG-GY018 trial to be presented at Society of Gynecologic Oncology (SGO) 2023 Annual Meeting and published simultaneously in New England Journal of Medicine

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health , Seagen Inc. , Provention Bio Inc. , Kimball International, Inc.

Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847. There is no cost or financial obligation to you.

Oak Street Health (NYSE – OSH)

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×